Drugs / PRO-231
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06363292 | Jan → May 2024 | bacterial conjunctivitis | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRO-231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06363292 ↗ |
| Route | Topical | “Route of administration: Topical ophthalmic.” NCT06363292 ↗ |